Is Protagonist Therapeutics, Inc. (PTGX) a Buy, Sell, or Hold?
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$43.8 USD
-$1.15 (-2.56%)
- Volume
- 320.16K
- Average Volume
- 689.4K
- Market Capitalization
- $2.61B
- P/E Ratio
- 15.84
- Dividend Yield
- 0.00%
- Price Target
- $55.00
- Year High
- $48.89
- Year Low
- $17.70
- Payout Ratio
- $0.00
- Current Ratio
- $10.70
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Market |
| CEO | Dr. Dinesh V. Patel Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PTGX |
| CUSIP | 74366E102 |
| CIK | 0001377121 |
| Web | https://www.protagonist-inc.com |
| Phone | 510 474 0170 |
| Currency | USD |
| Employees | 126 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.70 |
| Quick Ratio | 10.70 |
| Cash Ratio | 2.94 |
Sales & Book Value
| Annual Sales | $60M |
| Price / Sales | 8.06 |
| Cash Flow | 3.71 |
| Price / Cash Flow | 11.39 |
| Price / Book | 5.09 |
Price Target and Rating
| Average Stock Price Forecast | $55.00 |
| High Stock Price Forecast | $60.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -20.36% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.39 |
| Trailing P/E Ratio | 15.84 |
| PEG Ratio | 11.01 |
| P/E Growth | 11.01 |
| Net Income | $-78.96M |
| Net Margin | 52.76% |
| Pretax Margin | 53.45% |
| Return on Equity | 34.68% |
| Return on Assets | 28.29% |
Financials Score
| AltmanZ Score | 22.88 |
| Piotroski Score | 6.00 |
| Working Capital | 432.19M |
| Total Assets | 603.86M |
| Ebit | 148.22M |
| Market Cap | 2.61B |
| Total Liabilities | 71.94M |
Poll Results
About Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen B ... iotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
2024-11-22 07:30:00
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
2024-11-19 07:30:00
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
2024-11-13 13:06:16
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
2024-11-07 18:30:31
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago.
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-07 16:05:00
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in Q1 2025 Development candidate nomination for oral IL-17 peptide antagonist expected in Q4 2024 Cash, cash equivalents and marketable securities of $583.3 million as of September 30, 2024, anticipated to provide cash runway through end of 2027 NEWARK, CA / ACCESSWIRE / November 7, 2024 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. "Protagonist is approaching multiple transformational events with the pending readouts of JNJ-2113 in Phase 3 psoriasis studies this year, Phase 2b ulcerative colitis study in Q1 2025, and rusfertide Phase 3 study in polycythemia vera in Q1 2025," said Dinesh V.
Frequently Asked Questions
-
What is the current Protagonist Therapeutics, Inc. (PTGX) stock price?
-
Protagonist Therapeutics, Inc.(NASDAQ:PTGX) stock price is $43.8 in the last trading session. During the trading session, PTGX stock reached the peak price of $48.89 while $17.7 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was --2.56% while the dollar amount for the price change in PTGX stock was -$-1.15.
-
PTGX's industry and sector of operation?
-
The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PTGX?
-
Mr. Matthew M. Gosling J.D. | Executive Vice President & General Counsel
Dr. Dinesh V. Patel Ph.D. | Chief Executive Officer, President, Secretary & Director
Mr. Asif Ali | Executive Vice President & Chief Financial Officer
Dr. Suneel K. Gupta Ph.D. | Chief Development Officer
Dr. Mark Smythe Ph.D. | Founder & Vice President Technology -
How many employees does PTGX have?
-
Number of PTGX employees currently stands at 126. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, US.
-
Link for PTGX official website?
-
Official Website of PTGX is: https://www.protagonist-inc.com
-
How do I contact PTGX?
-
PTGX could be contacted at phone #510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, US.
-
How many shares of PTGX are traded daily?
-
The average number of PTGX shares traded daily for last 3 months was 689.4K.
-
What is the market cap of PTGX currently?
-
The market value of PTGX currently stands at $2.61B with its latest stock price at $43.8